Two major populations of myeloid-derived suppressor cells (MDSCs), monocytic MDSCs (M-MDSCs) and polymorphonuclear MDSCs (PMN-MDSCs) regulate immune responses in cancer and other pathologic conditions. Under physiologic conditions, Ly6C hi Ly6G − inflammatory monocytes, which are the normal counterpart of M-MDSCs, differentiate into macrophages and dendritic cells. PMN-MDSCs are the predominant group of MDSCs that accumulates in cancer. Here we show that a large proportion of M-MDSCs in tumor-bearing mice acquired phenotypic, morphological and functional features of PMN-MDSCs. Acquisition of this phenotype, but not the functional attributes of PMN-MDSCs, was mediated by transcriptional silencing of the retinoblastoma gene through epigenetic modifications mediated by histone deacetylase 2 (HDAC-2). These data demonstrate a new regulatory mechanism of myeloid cells in cancer.
A r t i c l e s Myelopoiesis is a tightly regulated hierarchical process of commitment to cell lineage. This process is altered in cancer, resulting in the expansion of relatively immature and activated myeloid cells, now termed MDSCs 1 . MDSCs negatively regulate immune responses and facilitate tumor metastasis and angiogenesis [2] [3] [4] , and contribute to the regulation of immune responses in chronic infectious diseases, sepsis, trauma, autoimmune diseases and transplantation [5] [6] [7] [8] [9] [10] . In mice, MDSCs are characterized by the dual expression of Gr-1 and CD11b. The immunosuppressive activity of these cells is associated with high levels of arginase, nitric oxide, reactive oxygen species (ROS), prostaglandin E2 and cytokines 3 . MDSCs lack markers of mature macrophages and dendritic cells (DCs), and include populations of immature myeloid cells and myeloid progenitors 3 . It is now established that MDSCs comprise two groups of cells with monocytic (M-MDSC) and polymorphonuclear (PMN-MDSC) morphology [11] [12] [13] [14] . In mice, M-MDSCs have low Gr-1 expression and are CD11b + Ly6C hi Ly6G − . M-MDSCs are highly immunosuppressive, exerting their effect largely in an antigen-nonspecific manner. In naive mice, this phenotype defines inflammatory monocytes, a subset of migratory monocytes that lack immunosuppressive activity 15 . PMN-MDSCs have high Gr-1 expression and are CD11b + Ly6C lo Ly6G + . These cells are moderately immunosuppressive, primarily via antigen-specific mechanisms. In naive mice, this phenotype characterizes polymorphonuclear neutrophils (PMNs) with no immunosuppressive activity. In cancer, PMN-MDSCs could represent a population of pathologically activated precursors of neutrophils 16, 17 . In cancer patients, M-MDSCs are defined as either CD14 + HLA-DR lo or CD11b + CD14 − CD33 + CD15 − cells, whereas PMN-MDSCs are defined as CD11b + CD14 − CD33 + CD15 + cells 18 .
M-MDSCs and PMN-MDSCs differ in their morphology and phenotype. They differ in gene expression profiles and activity of transcription factors, and use different factors to inhibit immune responses 2, 19 . It is assumed that M-MDSCs and PMN-MDSCs develop along different pathways involving monocyte and granulocyte progenitors, respectively. Accumulation of MDSCs is induced by various growth factors (GM-CSF, M-CSF and others) and proinflammatory cytokines (IL-6, IL-1β, IL-13 and others). Several transcription factors have been implicated in MDSC expansion, including STAT3, CEBPα and others 19, 20 . However, the mechanism preventing MDSCs from differentiation to macrophages and DCs remains unclear.
In this study, we investigated the fate of MDSCs in tumor-bearing hosts and provide evidence suggesting that in cancer the normal pathway of monocyte differentiation toward macrophages and DCs is altered to preferential differentiation toward PMN-MDSCs. This process is governed by epigenetic silencing of the retinoblastoma gene controlled by histone deacetylase 2 (HDAC-2).
A r t i c l e s
RESULTS

Accumulation of MDSC subsets in tumor-bearing hosts
To assess the accumulation of the two major groups of MDSCs, we used previously established phenotypic criteria of PMN-MDSCs as CD11b + Ly6G + Ly6C lo cells and M-MDSCs as CD11b + Ly6G − Ly6C hi cells (Fig. 1a) . In tumor-free mice, the CD11b + Ly6G + Ly6C lo phenotype defines neutrophils (PMNs) and CD11b + Ly6G − Ly6C hi monocytes. We evaluated the kinetics of MDSC accumulation in different transplantable tumor models (EL-4, 4T1 and LLC). We found substantial expansion of PMN-MDSCs in blood and spleens and a smaller, albeit significant (P < 0.05) increase in the number of these cells in the bone marrow (BM), which was associated with tumor progression ( Fig. 1b and Supplementary Fig. 1a) . In contrast, the increase in the proportion of M-MDSCs was relatively small. Similar changes in the amounts of PMN-MDSCs and M-MDSCs were seen in the absolute numbers of MDSC subsets ( Fig. 1c and Supplementary Fig. 1b) . To assess MDSC populations in a spontaneous tumor model, we used mice with targeted expression of the Kras oncogene in the lung (Kras/CC10 mice), which develop lung tumors around 7-8 weeks of age. Only expansion of PMN-MDSCs, but not of M-MDSCs, was detected in the spleens of [11] [12] week-old Kras/CC10 mice (Supplementary Fig. 1c) .
To compare the proliferation of PMN-MDSCs and M-MDSCs and their immediate precursors in vivo, we injected 5-bromodeoxyuridine (BrdU; thymidine analog incorporated by cycling cells) intraperitoneally into EL-4 tumor-bearing mice and measured its incorporation into M-MDSCs and PMN-MDSCs in BM and spleen cells 5 or 24 h later ( Fig. 1d,e ). As a control, we measured BrdU incorporation in monocytes and PMNs from naive tumor-free mice. M-MDSCs had a 5-6-fold greater BrdU incorporation than PMN-MDSCs did in BM of EL-4 tumor mice ( Fig. 1d) . We observed no differences in BrdU uptake between PMN-MDSCs from tumor-bearing mice and PMNs from naive mice; M-MDSCs from tumor-bearing mice incorporated more than twofold more BrdU than monocytes from naive mice did ( Fig. 1d ). Monocytes and PMNs from spleens of naive mice and PMN-MDSCs from spleens of tumor-bearing mice had similar BrdU uptake, whereas M-MDSCs incorporated 2-3-fold more BrdU (Fig. 1e) . We next investigated GM-CSF-driven expansion 16 of sorted populations of BM PMN-MDSCs and M-MDSCs in vitro, cultured with or without tumor explant supernatants. We evaluated the total number of recovered cells as well as cell proliferation. PMN-MDSCs and PMNs exhibited no proliferative activity and poor survival in culture. Tumor explant supernatants improved survival of PMNs and PMN-MDSCs without an effect on proliferation. In contrast, M-MDSCs proliferated and expanded much better than monocytes or PMN-MDSCs did ( Supplementary Fig. 2 and Fig. 1f ). However, the ratio between PMN-MDSCs and M-MDSCs remained largely unchanged in the total population of Gr-1 + CD11b + MDSCs in vitro (Fig. 1g) . Thus, despite the fact that M-MDSCs and their precursors had a higher proliferation rate than monocytes did, their accumulation in tumorbearing mice was barely detectable. In contrast, precursors of PMN-MDSCs proliferated at similar rates as the PMNs did but expanded dramatically in tumor-bearing hosts. In addition, PMN-MDSCs represented a large percentage of MDSCs during culture, despite the lack of expansion in vitro and their poor survival, suggesting that the pool of PMN-MDSCs may be replenished from M-MDSCs.
M-MDSCs, but not monocytes, differentiate to PMN-MDSCs
We asked whether PMN-MDSCs or M-MDSCs can differentiate to each other in culture. We cultured PMN-MDSCs and M-MDSCs sorted from the spleen of EL-4 TB mice for 3 d in GM-CSF. Although surviving PMN-MDSCs in culture retained their phenotype (CD11b + Ly6C lo Ly6G + ), more than 30% of cultured M-MDSCs downregulated Ly6C and expressed Ly6G to become CD11b + Ly6C lo Ly6G + cells, a phenotype corresponding to PMN-MDSCs ( Fig. 2a) . To compare the differentiation of monocytes and M-MDSCs, CD11b + Ly6C hi Ly6G − cells were sorted from BM of naive and tumor-bearing mice, and cultured in vitro with GM-CSF. After 5 d in culture, monocytes differentiated into Gr-1 − F4/80 + macrophages or Gr-1 − CD11c + DCs. Less than 10% of the cells expressed Ly6G (Fig. 2b) , and very few cells demonstrated polymorphonuclear morphology ( Fig. 2c) . In contrast, more than 40% of M-MDSCs cultured for 5 d acquired the phenotype (CD11b + Ly6C lo Ly6G + ) and the typical morphology of PMN-MDSCs (Fig. 2b,c) . Less than 10% of the cells generated from M-MDSCs had a DCs phenotype (Gr-1 − CD11c + ) and only 15% were macrophages (Gr-1 − F4/80 + ) ( Fig. 2b) . Culture of monocytes with tumor explant supernatants lead to a substantial increase in the generation of Ly6G + cells (25%) and a decrease in the presence of macrophages (38%) and DCs (12%) (Fig. 2b) . We obtained similar results with BM M-MDSCs from Kras/CC10 TB mice. Almost 50% of cells generated from A r t i c l e s M-MDSCs isolated from these mice expressed Ly6G and had a polymorphonuclear morphology ( Supplementary Fig. 3 ).
To verify that the Ly6G + cells generated from M-MDSCs were PMN-MDSCs, we determined the activity of the granulocyte markers myeloperoxidase (MPO) and naphthol-AS-D chloracetate esterase as well as production of ROS. Cells generated from M-MDSCs after 5 d of culture with tumor explant supernatants were sorted into Ly6G − Ly6C hi M-MDSCs and Ly6G + Ly6C lo PMN-MDSCs. CD11b + Ly6C lo Ly6G + PMN-MDSCs had a twofold greater activity of MPO ( Fig. 2d ) and more than a fivefold greater amount of ROS ( Fig. 2e ) than CD11b + Ly6C hi Ly6G − M-MDSCs did. The amount of ROS in PMN-MDSCs was similar to that in freshly isolated control spleen PMNs ( Fig. 2e) , whereas the activity of MPO in PMN-MDSCs was 50% of that in control PMNs (Fig. 2d) . Polymorphonuclear but not mononuclear cells generated from M-MDSCs stained positive for esterase ( Fig. 2f) .
We also analyzed the morphology of sorted monocytes and M-MDSCs. Both of these populations of cells comprised mainly mononuclear cells with some contamination of cells with cytologic features of promyelocytes. However, promyelocytes were present in equal proportions in freshly isolated monocytes and in M-MDSCs (data not shown). During 5-d culture, M-MDSCs exhibited a transition from promyelocyte morphology to neutrophils with ringed-shaped nuclei lacking primary granules and later to neutrophils with segmented nuclear lobes. This progression followed the conventional steps of differentiation of neutrophils and suggested that PMN-MDSCs derive from the promyelocyte population. M-MDSC-derived PMN-MDSCs, bona fide PMN-MDSCs freshly isolated from spleens of tumorbearing mice and PMNs from naive mice all had identical morphological features (data not shown). To determine whether PMN-MDSCs derived from M-MDSCs had immunosuppressive activity, we sorted CD11b + Ly6C lo Ly6G + cells from 3-d cultures of M-MDSCs grown with the cell-signaling molecule GM-CSF and tumor explant supernatants. These PMN-MDSCs potently inhibited T cell response ( Fig. 2g) . We could not generate granulocytic cells from F4/80 + tumorassociated macrophages after their culture with GM-CSF and tumor explant supernatants (data not shown).
To evaluate the fate of cells in vivo, we transferred sorted congenic CD45.1 + BM cells from EL-4 tumor-bearing mice to CD45.2 + EL-4 tumor-bearing recipients and evaluated the phenotype of donor cells 48 h after the transfer. Consistent with the results of in vitro experiments, surviving PMN-MDSCs from CD45.1 + donors retained their phenotype, whereas more than 60% of M-MDSCs from the CD45.1 + donors acquired the phenotype of PMN-MDSCs (Fig. 3a) . In addition, we compared the fate of monocytes and M-MDSCs using donor cells fluorescently labeled with 5chloromethylfluorescein diacetate (CMFDA). Two days after transfer of fluorescently labeled monocytes to naive recipients, very few CMFDA + donor cells expressed the phenotype typical for PMNs (CD11b + Ly6C lo Ly6G + ). In sharp contrast, the majority CMFDA + M-MDSCs transferred in tumor-bearing recipients expressed CD11b + Ly6C lo Ly6G + markers of PMN-MDSCs (Fig. 3b) . We obtained similar results when we transferred M-MDSCs to naive recipients. Within 2 d of transfer, only a few M-MDSCs became macrophages (Gr-1 − F4/80 + ) or DCs (Gr-1 − CD11c + ), whereas about 45% of transferred monocytes differentiated into DCs or macrophages in naive mice (Fig. 3b) . These data demonstrate that whereas in naive mice monocytes cannot differentiate to PMNs, in tumorbearing mice M-MDSCs can generate cells with CD11b + Ly6C lo Ly6G + phenotype of PMN-MDSCs in vitro and in vivo.
Retinoblastoma protein expression is low in MDSCs
To investigate the mechanism that drives monocyte and M-MDSC differentiation, we analyzed the gene expression profile of spleen M-MDSCs versus PMN-MDSCs. Because we noticed low expression of retinoblastoma genes in PMN-MDSCs ( Supplementary Table 1 and data not shown), we looked more closely at Rb1 expression in MDSCs. Splenocytes isolated from tumor-bearing mice had lower amounts of total and phosphorylated Rb1 than splenocytes from naive mice did (Fig. 4a) . This decrease correlated with tumor progression and was associated with increased expression of the transcription factor E2F1 (Fig. 4b) , suggesting that Rb1 downregulation had functional consequences. When we separated splenocytes from EL-4 tumorbearing mice on the basis of Gr-1 expression, the Gr-1 − cells contained high Rb1, whereas Rb1 was practically undetectable in Gr-1 + cells ( Fig. 4c) , indicating that the decrease in Rb1 expression was associated with an accumulation of MDSCs in spleens. This was associated with the downregulation of Rb1 gene expression ( Fig. 4d) .
We investigated the expression of Rb1 in two MDSC subsets in spleen. M-MDSCs had similar amounts of Rb1 protein as did mature myeloid cells (PMNs and DCs) or lymphoid cells (T or B lymphocytes), whereas PMN-MDSCs had barely detectable amounts of Rb1 (Fig. 4e) . In cells isolated from either spleen or BM, Rb1 mRNA expression was 3-5-fold higher in M-MDSCs than in PMN-MDSCs ( Fig. 4f) . PMN-MDSCs from spleens of tumor-bearing mice had three times lower expression of rb1 mRNA (Fig. 4g ) and a substantially lower amount of Rb1 protein (Fig. 4h ) than PMNs isolated from spleens of naive mice. Freshly isolated BM PMNs from naive mice had low amounts of Rb1 protein, similar to that in PMN-MDSCs. However, during culture, Rb1 was rapidly upregulated in PMNs, whereas it remained low in PMN-MDSCs ( Fig. 4i) . Thus, in contrast to PMNs and other mature myeloid cells, PMN-MDSCs did not upregulate Rb1 protein after leaving the BM. BM M-MDSCs from tumor-bearing mice had significantly lower expression of Rb1 mRNA ( Fig. 4j) and Rb1 protein ( Fig. 4k ) than monocytes from naive mice. Thus, PMN-MDSCs had much less Rb1 protein compared to PMNs, and M-MDSCs had less Rb1 protein compared to monocytes.
Rb1 correlates with abnormal M-MDSC differentiation
We next asked whether Rb1 downregulation is required for M-MDSCs to acquire characteristics of PMN-MDSCs. We used immunofluores- A r t i c l e s cent staining to study the pattern of Rb1 expression in M-MDSCs, using splenocytes from Rb1-deficient mice as a control ( Supplementary  Fig. 4 ). Rb1 expression was lower in BM M-MDSCs than in BM monocytes but was also heterogeneous in both types of cells ( Fig. 5a) A r t i c l e s the case of M-MDSCs), to decrease the possibility of labeling proliferating precursors cells (Supplementary Fig. 5 ). The proportion of Hoechst low cells was slightly higher than that of Hoechst high cells among monocytes, whereas Hoechst low cells were the predominant population (66%) among M-MDSCs (Supplementary Fig. 5 ). All Hoechst low M-MDSCs were Rb1 − , similar to PMN-MDSCs, whereas the all Hoechst high M-MDSCs were Rb1 + (Fig. 5b) . Freshly isolated Hoechst low monocytes had relatively low expression of Rb1 (albeit higher than in M-MDSCs; Fig. 5c ) and they rapidly upregulated Rb1 expression during culture. In contrast, Rb1 expression in Hoechst low M-MDSCs remained unchanged ( Fig. 5d,e ). Thus, Hoechst 33342 labeling was closely associated with Rb1 expression.
We next asked whether Hoechst high and Hoechst low cells differed in their ability to differentiate to myeloid cells. Hoechst high and Hoechst low monocytes differentiated to macrophages and DCs equally well, with few Ly6G + cells generated from either of these two populations (Fig. 5f) . Hoechst high M-MDSCs exhibited the same pattern of differentiation as monocytes did, whereas the majority of Hoechst low M-MDSCs became Ly6G + , with only 20% of cells differentiating in macrophages or DCs (Fig. 5f) . Thus, BM M-MDSCs from tumor-bearing mice contain a large population of Rb1 low cells, which, in contrast to Rb1 + M-MDSCs and monocytes, differentiate predominantly into PMN-MDSCs.
M-MDSCs differentiate to PMN-MDSCs in cancer patients
In human cancer patients, CD11b + CD14 − CD33 + CD15 + or CD66b + cells are defined as immunosuppressive PMN-MDSCs, and CD11b + CD14 − CD33 + CD15 − cells as immunosuppressive M-MDSCs [21] [22] [23] (a typical profile is presented in Supplementary Fig. 6 ). In healthy donors, very few mononuclear cells had an MDSC phenotype, with monocytic cells outnumbering polymorphonuclear cells 3:1 (Fig. 6a) . In contrast, in patients with pancreatic, lung, and head and neck cancers, 10-20% of mononuclear cells were classified as MDSCs, with a PMN-MDSC:M-MDSC ratio of more than 5:1 (Fig. 6a) . Thus, similar to the results observed in mice, PMN-MDSCs were the predominant population of MDSCs in patients with various cancers.
To investigate whether human monocytes and M-MDSCs differentiate to granulocytic cells, isolated CD14 + monocytes (>80% were HLA-DR + cells) from BM of healthy donors and patients with multiple myeloma were cultured for 5 d with GM-CSF in the presence or absence of tumor cells conditioned medium. These cultures did not generate CD66b + cells (Supplementary Fig. 7) , demonstrating a lack of granulocytic differentiation. Sorted CD14 + HLA-DR −/low cells, which represent M-MDSCs in cancer patients 24, 25 , did not produce CD66b + cells when isolated from BM of healthy donors (Fig. 6b) . In contrast, CD14 + HLA-DR −/low cells from the BM of multiple myeloma patients generated ~8% CD66b + cells (Fig. 6b) , and cells with polymorphonuclear morphology were clearly visible in the cultures (Fig. 6c) . Consistent with the results obtained in Hoechst labeled M-MSDCs in mice, CD14 + HLA-DR −/low cells did not proliferate in the culture, as measured by BrdU incorporation, whereas CD14 + HLA-DR high cells actively proliferated (Fig. 6d) . Small numbers of M-MDSCs sorted from the peripheral blood of patients with non-small cell lung cancer and renal cell cancer did not generate cells with a granulocytic phenotype (CD66b + ) in vitro (data not shown).
We next evaluated the expression of RB1 in PMN-MDSCs and M-MDSCs isolated from cancer patients. In healthy donor cells, a small number of PMNs sorted from the mononuclear fraction had either a similar or higher expression of RB1 as the monocytic cells from the same fraction, whereas PMN-MDSCs from cancer patients had much lower RB1 expression compared to M-MDSCs (Fig. 6e) . Expression of RB1 was substantailly lower in PMN-MDSCs sorted from the mononuclear fraction than in PMN cells sorted from high-density Percoll gradient (standard for PMN isolation; Fig. 6f ). CD14 + HLA-DR hi cells from the BM of multiple myeloma patients had higher RB1 expression than CD14 + HLA-DR −/low cells did (Fig. 6g) . These data indicate that PMN-MDSCs could be generated from M-MDSCs in cancer patients and that this process is associated with low RB1 expression. (Fig. 7a) . Consistent with a previous observation 26 , the loss of Rb1 resulted in increased number of cells in spleens compared to wildtype mice (data not shown). The proportion of monocytes in the spleen was similar in Rb1-deficient and wild-type mice, whereas the proportion of PMN cells was dramatically increased in Rb1deficient mice (Fig. 7b) . When we cultured Rb1-deficient and wild-type BM sorted monocytes for 5 d with GM-CSF, only a small proportion of wild-type monocytes became Ly6G + (Fig. 7c) and acquired a polymorphonuclear morphology (Fig. 7d) . In contrast, 20% of monocytes from Rb1-deficient mice acquired the phenotype (Ly6G + ) and morphology of PMNs (Fig. 7c,d) . Rb1 deficiency was not sufficient to generate cells with immunosuppressive activity. Sorted CD11b + Ly6C lo Ly6G + cells from spleens of Rb1-deficient mice did not inhibit T cell response to CD3 and CD28 antibodies (data not shown). However, immunogeneic EG7 tumors (EL4 tumor expressing chicken ovalbumin) grew much faster in Rb1-deficient mice than in their wilt-type littermates (Fig. 7e) , indicating that in a tumor environment these cells could acquire immunosuppressive features and promote tumor growth. However, expansion of granulocytes may affect other cells that are important for induction of immune responses in Rb1-deficient mice.
We then asked whether upregulation of Rb1 in M-MDSCs affects their differentiation. We infected Hoechst low M-MDSCs isolated from the BM of EL-4 tumor-bearing mice with either adenovirus expressing Rb1 (Ad-Rb1-GFP) or control adenovirus (Ad-GFP) and then cultured the cells for 4 d with GM-CSF and tumor explant supernatants. Rb1
Gr-1 − CD11c + DCs and almost a twofold increase in the proportion of Gr-1 − F4/80 + macrophages from GFP + M-MDSCs, compared to GFP + , control-transduced cells (Fig. 7f) . We observed no differences in the proportion of PMN-MDSCs among GFP − cells (Fig. 7g) . Thus, loss of Rb1 expression was associated with abnormal regulation of myeloid cell differentiation in cancer.
HDAC-2 mediates Rb1 silencing in myeloid cells in cancer
We tested several mechanisms of epigenetic regulation of gene expression and found that inhibition of histone deacetylases (HDACs) with trichostatin A upregulated Rb1 expression during differentiation of enriched mixed population of hematopoietic progenitor cells in the presence of tumor explant supernatants (data not shown). Several pan-HDAC inhibitors, such as valproic acid (VPA), suberoylanilide hydroxamic acid and panobinostat (LBH-589) upregulated expression of Rb1 mRNA and Rb1 protein in PMN-MDSCs isolated from tumor-bearing mice and cultured with tumor explant supernatants (Fig. 8a,b) .
To address whether HDAC inhibition could affect differentiation of myeloid cells in cancer, we isolated Hoechst low M-MDSCs from BM of tumor-bearing mice, cultured them in the presence of GM-CSF and tumor explant supernatants for 24 h, with and without VPA, and analyzed the cells 4 d after removing VPA from the culture. The total number of recovered cells was not affected by VPA treatment (data not shown). Consistent with the results described above, in the absence of VPA, a substantial proportion of M-MDSCs became Ly6G + . More than 60% of the cells retained expression of Gr-1 and less than 30% of cells were macrophages or DCs (Fig. 8c) . VPA treatment of M-MDSCs induced less than 15% of Ly6G + cells, whereas 
Rb1 regulates myeloid differentiation in cancer
To evaluate the direct role of Rb1 in regulation of monocyte differentiation we used Rb1 loxP/loxP mice crossed with Mx1-Cre mice, in which Rb1 deletion was induced by repeated polyino-overexpression decreased the proportion of PMN-MDSCs ( Fig. 7f) and induced a sixfold increase in the proportion of npg A r t i c l e s more than 60% of the cells were macrophages and DCs (Fig. 8c) .
In similar experiments, monocytes isolated from BM of Rb1-deficient mice exhibited defective differentiation toward macrophages and DCs. More than 50% of the cells retained Gr-1 expression, and 25% of cells acquired the Ly6G marker (Fig. 8d) . Treatment with VPA did not increase the proportion of DCs and macrophages differentiated from Rb1-deficient BM monocytes (Fig. 8d) . Thus, even in the presence of tumor explant supernatants, the HDAC inhibitor redirected M-MDSC differentiation toward macrophages and DCs. This effect was absent in Rb1-deficient cells, suggesting that epigenetic regulation of Rb1 is important during abnormal myeloid cell differentiation.
Using chromatin immunoprecipitation (ChIP), we investigated the role of HDAC in silencing of the Rb1 gene in PMN-MDSCs. We used mature DCs as a control. Inhibition of HDAC with LBH-589 upregulated histone acetylation of the Rb1 promoter in PMN-MDSCs but not in DCs (Fig. 8e) . We found no specific recruitment of HDAC-1, HDAC-3 or HDAC-6 to the Rb1 promoter in PMN-MDSCs. However, PMN-MDSCs had a much higher level of HDAC-2 association with the Rb1 promoter than DCs did (Fig. 8f) . In addition, PMN-MDSCs had significantly (P = 0.0001) greater HDAC-2 association with the Rb1 promoter than PMNs did (Fig. 8g) . Culture of PMN-MDSCs with GM-CSF resulted in a gradual increase in the expression of Rb1 (Fig. 8h) and this was associated with a reduction in the association of HDAC-2 with the Rb1 promoter ( Fig. 8i) . To test whether HDAC-2 is involved in silencing Rb1 expression in MDSCs, we downregulated HDAC-2 and HDAC-1 expression in MDSCs using small interfering RNA (siRNA; Supplementary  Fig. 8 ). Downregulation of HDAC-2, but not of HDAC-1, induced significant (P = 0.007) upregulation of Rb1 expression in MDSCs cultured with tumor explant supernatants (Fig. 8j) . Thus, silencing of Rb1 expression in MDSCs was mediated by HDAC-2.
DISCUSSION
Although granulocytic and monocytic cells originate from common myeloid progenitors, they develop along divergent pathways. The monocytic pathway includes differentiation of monocytes into A r t i c l e s macrophages and DCs in tissues 27 . Granulocytic cells undergo several terminal stages of PMN development 28 . Although M-MDSCs and PMN-MDSCs have been believed to differentiate along the same developmental pathways as monocytes and PMNs, respectively, based on our results we propose that, in tumor-bearing hosts, a large proportion of M-MDSCs acquire the ability to differentiate to PMN-MDSCs. Monocytes are characterized by high plasticity and are known to change the expression of the receptors under various conditions 29 . Although mature macrophages and PMNs are functionally distinct, they have similar transcriptional profiles 30 . We observed that M-MDSCs, in addition to downregulating Ly6C expression, upregulated the granulocyte-specific marker Ly6G. Immunosuppressive CD11b + Ly6C lo Ly6G + cells generated from M-MDSCs had typical PMN morphology, were positive for naphthol-AS-D esterase and had much higher MPO activity and amount of ROS than did CD11b + Ly6C hi Ly6G − cells differentiated under the same conditions. All these features distinguish PMNs from monocytes and suggest that cells generated from M-MDSCs could be PMN-MDSCs.
It was possible that in contrast to monocytes, M-MDSCs could be enriched for granulocytic progenitors that could expand in vitro or in vivo. However, the lack of Ly6G expression and typical mononuclear morphology in the absence on morphologically identifiable neutrophils made the possibility that M-MDSCs could be enriched for nondividing, late-stage progenitors unlikely. In addition, our data demonstrated that in contrast to late-stage PMN precursors, M-MDSCs had very low level of MPO activity and ROS 11 . Expression of Ly6C hi by M-MDSCs made unlikely the possibility that these cells could be enriched for dividing early progenitors because high Ly6C expression is not associated with early granulocyte progenitors. Our morphological analysis showed that M-MDSCs and monocytes included similar amounts of promyelocytic cells. The fact that PMN-MDSCs were generated mostly from nonproliferating or poorly proliferating (Hoechst low ) population of M-MDSCs also provides an argument against the possibility that PMN progenitors among M-MDSCs were responsible for differentiation into PMN-MDSCs.
Thus, it appears that in cancer M-MDSCs probably acquire the ability to differentiate into PMN-MDSCs and may represent an important pathway for the accumulation of these cells.
The three members of the retionoblastoma family of transcriptional regulators, Rb1, p107 and p130 integrate multiple cellular signals to control cellular proliferation and differentiation [31] [32] [33] . Hypophosphorylated retionoblastoma proteins bind to E2F transcription factor(s) and act as a strong transcriptional repressors 34 . Retinoblastoma proteins also promote terminal differentiation by inducing tissue-specific gene expression. Monocytic differentiation is associated with the hypophosphorylation of Rb1 (ref. 35 ) and the monocytic lineage commitment of human progenitor cells, correlated with high levels of Rb1 (ref. 36) . In earlier reports, the loss of Rb1 function had no direct effect on the cell cycle of hematopoietic stem cells, except under stress conditions 37 , and the loss of Rb1 was associated with mild myeloid expansion 38 . More recently, the genetic inactivation of Rb1 resulted in a substantial expansion of immature myeloid cells 26, 39 . Our data indicated that MDSCs, especially PMN-MDSCs, had less Rb1, which was not associated with an increased proliferation of these cells. This was not surprising because deletion of Rb1 in mice does not necessarily result in an increased proliferation of targeted cells 37, 38 . The amount of Rb1 in BM monocytes or PMNs increased rapidly during culture, whereas in M-MDSCs or PMN-MDSCs it remained low. The data obtained from the experiments with Rb1 overexpression in M-MDSCs and Rb1-deficient mice, indicate a direct role of Rb1 in regulation of M-MDSC differentiation toward PMN-MDSCs. However, the effect was more modest than with tumor-derived factors, which may suggest that other pocket proteins could be involved.
Our data suggested that silencing of Rb1 could be mediated by HDAC-2, which is known to be involved in modulating the repressive activity of Rb on promoters of E2f genes and in the expression of genes involved in differentiation of various cells 40 . Rb1 can be associated with class I HDACs (HDAC1-HDAC3) 41, 42 . Here we showed that HDAC-2 can directly interact with Rb1 promoter and participate in silencing of Rb1 expression. Several transcription factors were previously implicated in Rb1-mediated regulation of cell differentiation. Among them, CEBP-β and Id2 (refs. [43] [44] [45] can be involved in the regulation of myeloid cell differentiation. The role of these factors in observed effects needs additional investigation.
Thus, silencing of Rb1 expression in monocytes and other myeloid progenitors may be critical in the accumulation of a population of PMN-MDSCs. If the specific role of HDAC-2 in this process is confirmed, it may potentially open a new opportunity for the selective therapeutic targeting of these cells in cancer and possibly in other pathologic conditions.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper. primary antibody (anti-acetyl H3/H4, anti-HDAC-1, anti-HDAC-2, anti-HDAC-3 or anti-HDAC-6) at 4 °C. The immunocomplexes were recovered by adding 60 µl of a salmon sperm DNA/Protein A Agarose 50% slurry, followed by washing, reversing cross-linking with NaCl and recovering DNA by phenol/chloroform extraction and ethanol precipitation. The DNA was amplified by quantitative PCR using the primer specific for Rb1 promoter sequence: forward, 5′-TACTTGGGTTCGAGTCCTCTGCCAG-3′, reverse, 5′-AGTTGGCCGTGTTCATGCG-3′.
Statistical analysis. Statistical analysis was performed using a two-tailed Student's t-test and GraphPad Prism 5 software (GraphPad Software), and considered significant at P < 0.05. 
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